Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
Self-citationManagement of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32409-1 · Cited by 879
“14 Low dose rivaroxaban prevents venous thromboembolism after orthopaedic surgery, 15 and the Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-2) trial 16 showed that low-dose rivaroxaban (2·5 mg twice a day) used in addition to dual antiplatelet therapy reduced major adverse…”
Self-citationRivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Self-citationLassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Portman, R. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810773 · Cited by 695
Mega, J., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V, Barnathan, E., Bordes, P., Witkowski, A., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60738-8 · Cited by 688
Self-citationAnderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000975 · Cited by 626
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
“The dose regimens of rivaroxaban selected for the phase III studies [5–12] that underpin these approvals were based on data from an extensive phase I and phase II clinical study program [13–16].”
MethodGogarten, W., Vandermeulen, E., Van Aken, H., Kozek, S., Llau, J. V., & Samama, C. M. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32833f6f6f · Cited by 529
Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Self-citationAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
Anderson, D. R., Dunbar, M., Murnaghan, J., Kahn, S. R., Gross, P., Forsythe, M., Pelet, S., Fisher, W., Belzile, E., Dolan, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712746 · Cited by 439
Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., Lufft, V., Wand, D. D., Philipp, T., & Bruck, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03753.x · Cited by 432
Holster, I. L., Valkhoff, V. E., Kuipers, E. J., & Tjwa, E. T. T. L. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.041 · Cited by 408
Dahl, O., Huo, M., Kurth, A., Hantel, S., Hermansson, K., Schnee, J., Friedman, R., Eriksson, B., & for the RE-NOVATE II Study Group (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0679 · Cited by 401
“The reduction in risk for this clinically relevant outcome (number needed to treat, 52) is similar to that observed with other novel anticoagulants in patients undergoing hip arthroplasty (21, 22).”
BackgroundResultSelf-citationStein, P. D., Chenevert, T. L., Fowler, S. E., Goodman, L. R., Gottschalk, A., Hales, C. A., Hull, R. D., Jablonski, K. A., Leeper, K. V., Naidich, D. P., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-7-201004060-00008 · Cited by 392
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood · doi:10.1182/blood-2008-05-160143 · Cited by 342
“Adverse event, n (%) 9 (7) 7 (5) 5 (4) 5 (4)”
Self-citationMueck, W., Lensing, A. W. A., Agnelli, G., Decousus, H., Prandoni, P., & Misselwitz, F. (2011) · Clinical Pharmacokinetics · doi:10.2165/11595320-000000000-00000 · Cited by 327
Self-citationLey, E. J., Brown, C. V. R., Moore, E. E., Sava, J. A., Peck, K., Ciesla, D. J., Sperry, J. L., Rizzo, A. G., Rosen, N. G., Brasel, K. J., et al. (2020) · Journal of Trauma and Acute Care Surgery · doi:10.1097/ta.0000000000002830 · Cited by 294
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Self-citationGuyatt, G. H., Akl, E. A., Crowther, M. A., Gutterman, D. D., & nemann, H. J. S. (2013) · Cited by 309
Garcia, D., Libby, E., & Crowther, M. A. (2010) · Blood · doi:10.1182/blood-2009-09-241851 · Cited by 284
Rivaroxaban: A New Oral Factor Xa Inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., Mueck, W., & Laux, V. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.202978 · Cited by 276
Lassen, M. R., Eriksson, B., Gent, M., Berkowitz, S., Misselwitz, F., Bandel, T., Homering, M., Westermeier, T., Kakkar, A., & Turpie, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-09-0601 · Cited by 269
Self-citationKubitza, D., Becka, M., Roth, A., & Mueck, W. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802361499 · Cited by 268
Gomez-Outes, A., Terleira-Fernandez, A. I., Suarez-Gea, M. L., & Vargas-Castrillon, E. (2012) · BMJ · doi:10.1136/bmj.e3675 · Cited by 261
Eikelboom, J. W., & Weitz, J. I. (2010) · Circulation · doi:10.1161/circulationaha.109.853119 · Cited by 245
Thromboembolism prophylaxis in orthopaedics: an update
Flevas, D. A., Megaloikonomos, P. D., Dimopoulos, L., Mitsiokapa, E., Koulouvaris, P., & Mavrogenis, A. F. (2018) · EFORT Open Reviews · doi:10.1302/2058-5241.3.170018 · Cited by 229
Kim, J. L., Park, J.-H., Han, S.-B., Cho, I. Y., & Jang, K.-M. (2017) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.08.026 · Cited by 235
Contant, G., Spiro, T., Perzborn, E., Guinet, C., Gourmelin, Y., Flem, L., Rohde, G., Martinoli, J., Samama, M., & Laboratories, F. T. R. A.-F. X. C. A. F. T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0391 · Cited by 232
Pros and cons of new oral anticoagulants
Bauer, K. A. (2013) · Hematology · doi:10.1182/asheducation-2013.1.464 · Cited by 226
New oral anticoagulant drugs in cardiovascular disease
Lip, G., Peter, K., & Ahrens, I. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-05-0327 · Cited by 227
“RECORD1 and RECORD2 both demonstrated superiority of rivaroxaban compared to enoxaparin 40 mg QD.”
BackgroundAllogeneic Blood Transfusions and Postoperative Infections After Total Hip or Knee Arthroplasty
Friedman, R., Homering, M., Holberg, G., & Berkowitz, S. D. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01268 · Cited by 230
Self-citationAnderson, D. R., Dunbar, M. J., Bohm, E. R., Belzile, E., Kahn, S. R., Zukor, D., Fisher, W., Gofton, W., Gross, P., Pelet, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00004 · Cited by 223
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0014-6 · Cited by 201
“The orthopedic surgery program compared rivaroxaban to enoxaparin for VTE prevention in patients undergoing total hip and total knee arthroplasty [76–79].”
MethodFumery, M., Xiaocang, C., Dauchet, L., Gower-Rousseau, C., Peyrin-Biroulet, L., & Colombel, J.-F. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.09.021 · Cited by 204
Kubitza, D., Roth, A., Becka, M., Alatrach, A., Halabi, A., Hinrichsen, H., & Mueck, W. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12054 · Cited by 205
Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Eikelboom, J. W., Karthikeyan, G., Fagel, N., & Hirsh, J. (2009) · Chest · doi:10.1378/chest.08-2655 · Cited by 205
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
Lieberman, J. R., & Hsu, W. K. (2005) · The Journal of Bone & Joint Surgery · doi:10.2106/jbjs.d.03033 · Cited by 182
Lyman, G. H. (2011) · Cancer · doi:10.1002/cncr.25714 · Cited by 190
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
Eriksson, B. I., Quinlan, D. J., & Eikelboom, J. W. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-062209-095159 · Cited by 194
Self-citationHenke, P. K., Kahn, S. R., Pannucci, C. J., Secemksy, E. A., Evans, N. S., Khorana, A. A., Creager, M. A., Pradhan, A. D., & On behalf of the American Heart Association Advocacy Coordinating Committee (2020) · Circulation · doi:10.1161/cir.0000000000000769 · Cited by 176
Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients
Friedman, R. J., Hess, S., Berkowitz, S. D., & Homering, M. (2013) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-013-3049-9 · Cited by 194
Self-citationKakkos, S. K., Caprini, J. A., Geroulakos, G., Nicolaides, A. N., Stansby, G., Reddy, D. J., & Ntouvas, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005258.pub3 · Cited by 165
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement
Rajesparan, K., Biant, L. C., Ahmad, M., & Field, R. E. (2009) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.91b6.22393 · Cited by 184
Steiner, T., Böhm, M., Dichgans, M., Diener, H.-C., Ell, C., Endres, M., Epple, C., Grond, M., Laufs, U., Nickenig, G., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0560-7 · Cited by 183
Eriksson, B. I., Kakkar, A. K., Turpie, A. G. G., Gent, M., Bandel, T.-J., Homering, M., Misselwitz, F., & Lassen, M. R. (2009) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.91b5.21691 · Cited by 177
Self-citationNarouze, S., Benzon, H. T., Provenzano, D., Buvanendran, A., De Andres, J., Deer, T., Rauck, R., & Huntoon, M. A. (2017) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 164
Mueck, W., Schwers, S., & Stampfuss, J. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-10 · Cited by 165
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor
Kreutz, R., Llau, J., Norrving, B., Haas, S., & Turpie, A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0209 · Cited by 168
Self-citationLow risk of thromboembolic complications after fast-track hip and knee arthroplasty
Husted, H., Otte, K. S., Kristensen, B. B., Ørsnes, T., Wong, C., & Kehlet, H. (2010) · Acta Orthopaedica · doi:10.3109/17453674.2010.525196 · Cited by 162
“…regardless of type (whether chemoprophylactic or mechanical) and duration of thromboprophylaxis (up to 36 days) (Mantilla et al. 2002, Blom et al. 2006, Tarity et al. 2006, Lachiewiicz and Soileau 2006, 2007, Samama et al. 2007, Eriksson et al. 2008, Aynardi et al. 2009, Lassen et al. 2009).”
BackgroundInfluentialSamama, M. M. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2010.09.008 · Cited by 163
“The efficacy and safety of rivaroxaban (10 mg once daily [od]) for the preventionofVTEwere investigated in four large-scale, phase III studies in patients undergoing THR or TKR surgery [48–51].”
BackgroundManaging New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
Levy, J. H., Faraoni, D., Spring, J. L., Douketis, J. D., & Samama, C. M. (2013) · Anesthesiology · doi:10.1097/aln.0b013e318289bcba · Cited by 165
Freyburger, G., Macouillard, G., Labrouche, S., & Sztark, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.001 · Cited by 157
Drug and dietary interactions of the new and emerging oral anticoagulants
Walenga, J. M., & Adıgüzel, C. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02286.x · Cited by 152
Readmissions after fast-track hip and knee arthroplasty
Husted, H., Otte, K. S., Kristensen, B. B., Ørsnes, T., & Kehlet, H. (2010) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-010-1131-2 · Cited by 152
Cohen, A. T., Eriksson, B. I., Puskas, D., Shi, M., Bocanegra, T. S., Weitz, J. I., & Raskob, G. E. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-02-0142 · Cited by 146
Self-citationFriedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 141
“This percentage is consistent with that reported in contemporary studies using venography as an endpoint [4,15,16].”
ResultSelf-citationFuji, T., Wang, C., Fujita, S., Kawai, Y., Nakamura, M., Kimura, T., Ibusuki, K., Ushida, H., Abe, K., & Tachibana, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.011 · Cited by 143
“However, a 55% relative risk reduction in primarily asymptomatic DVT was used as evidence for the use of vitamin K antagonist prophylaxis in the 2012American College of Chest Physicians [19], and this endpoint is also consistent with phase 3 studies of other NOACs assessing the prevention of VTE after TKA [20–23].”
ResultRivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests
Asmis, L. M., Alberio, L., Angelillo‐Scherrer, A., Korte, W. C., Mendez, A., Reber, G., Seifert, B., Stricker, H. J., Tsakiris, D. A., & Wuillemin, W. A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.031 · Cited by 140
“Single dosing with no monitoring was successfully used in all the phase III studies performed so far [5–8].”
BackgroundMethodMiller, C., Dorreen, A., Martel, M., Huynh, T., & Barkun, A. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 138
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
Pinto, D. J. P., Smallheer, J. M., Cheney, D. L., Knabb, R. M., & Wexler, R. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100146h · Cited by 138
Pedersen, A. B., Sørensen, H. T., Mehnert, F., Overgaard, S., & Johnsen, S. P. (2010) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00882 · Cited by 141
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Pearson, S., Troughton, R., & Richards, A. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1112233 · Cited by 130
Ufer, M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-09-0659 · Cited by 129
“In the RECORD 1 non-inferiority/superiority trial, 4,591 patients undergoing THR were enrolled and rivaroxaban was compared with enoxaparin over 31–39 days of treatment (64).”
MethodFrost, C. E., Song, Y. J., Barrett, Y. C., Wang, J. J. J., Pursley, J. M., Boyd, R. A., & LaCreta, F. P. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s61131 · Cited by 139
Cohen, A. T., Spiro, T. E., Buller, H. R., Haskell, L. P., Hu, D., Hull, R. D., Mebazaa, A., Merli, G. J., Schellong, S., Spyropoulos, A. C., et al. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0549-x · Cited by 123
“which demonstrated rivaroxaban 10 mg od had comparable efficacy and safety to enoxaparin 40 mg od; phase III studies confirmed this [5, 6, 8, 35, 36].”
BackgroundForster, R., & Stewart, M. C. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004179.pub2 · Cited by 135
Oral Direct Factor Xa Inhibitors
Yeh, C. H., Fredenburgh, J. C., & Weitz, J. I. (2012) · Circulation Research · doi:10.1161/circresaha.112.276741 · Cited by 131
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.5 · Cited by 116
Zhang, Z.-H., Shen, B., Yang, J. Y., Zhou, Z., Kang, P., & Pei, F. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0470-0 · Cited by 119
“Results Screening results We included 54 papers [11-64] from 226 identified titles, in which about 1,150,000 patients from more than 30 countries and 28 classes of factors were examined.”
BackgroundEvolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Portal vein thrombosis in cirrhosis: Controversies and latest developments
Harding, D., Perera, M. T. P. R., Chen, F. E., Olliff, S. P., & Tripathi, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6769 · Cited by 119
Jørgensen, C. C., Jacobsen, M. K., Søballé, K., Hansen, T. B., Husted, H., Kjærsgaard‐Andersen, P., Hansen, L. T., Laursen, M. B., & Kehlet, H. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003965 · Cited by 121
Hachey, K. J., Hewes, P. D., Porter, L. P., Ridyard, D. G., Rosenkranz, P., McAneny, D. B., Fernando, H. C., & Litle, V. R. (2015) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2015.08.039 · Cited by 112
“25,26 These studies demonstrated a relative risk reduction of as much as 88 % for major VTE (including proximal DVT, nonfatal PE, and death from VTE) in favor of rivar-oxaban.”
BackgroundEvaluation of Drug-Induced Serious Hepatotoxicity (eDISH)
Watkins, P. B., Desai, M. G., Berkowitz, S. D., Peters, G. R., Horsmans, Y., Larrey, D. G., & Maddrey, W. C. (2011) · Drug Safety · doi:10.2165/11586600-000000000-00000 · Cited by 109
“There were no imbalances between the treatment groups in terms of demographic characteristics, including age, sex and body mass index.([5-8])”
BackgroundLevy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
Gross, P. L., & Weitz, J. I. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.98 · Cited by 124
“In a series of phase III trials comparing once-daily rivaroxaban with enoxaparin for VTE prophylaxis after elective hip or knee replacement, rivaroxaban was shown to be more effective than enoxaparin and did not increase the risk of major bleeding”
BackgroundEdoxaban: A New Oral Direct Factor Xa Inhibitor
Camm, A. J., & Bounameaux, H. (2011) · Drugs · doi:10.2165/11595540-000000000-00000 · Cited by 112
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
Mavrakanas, T. A., & Bounameaux, H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.12.007 · Cited by 117
“The rate of major bleeding was not significantly different between the groups (Eriksson et al., 2008).”
BackgroundThe New Oral Anticoagulants in Clinical Practice
Gonsalves, W. I., Pruthi, R. K., & Patnaik, M. M. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.03.006 · Cited by 112
Calder, J. D. F., Freeman, R., Domeij-Arverud, E., van Dijk, C. N., & Ackermann, P. W. (2016) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1007/s00167-015-3976-y · Cited by 111
“However, most studies investigating VTE are conducted in patients undergoing major orthopaedic surgery at or above the knee [4, 5, 12, 13, 17, 42, 49, 68, 72].”
BackgroundGu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed · doi:10.2450/2015.0096-15 · Cited by 127
New oral anticoagulants in development
Weitz, J. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-07-0434 · Cited by 104
“This result confirms the benefit of extended over short-term prophylaxis in THR patients.”
MethodInfluential
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.